GenSight Biologics appoints Mohamed Genead as chief medical officer

Thursday, May 4, 2017

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced it has appointed Mohamed Genead, M.D., as chief medical officer. Dr. Genead brings more than 15 years of experience to the role, including his most recent role as vice president & global therapeutic area head for Ophthalmology/Retina Gene Therapy at Biogen.

[Read More]

Allergan names Daphne Karydas SVP, Global Investor Relations & Strategy

Tuesday, April 11, 2017

Allergan, a global biopharmaceutical company, announced that Daphne Karydas will join the company as senior vice president of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Karydas will lead the company’s engagement with the investment community, and will work with the company’s executive leadership team to develop and execute the company’s long-term business strategy. Karydas will report to Tessa Hilado, chief financial officer of Allergan.

[Read More]

Allergan, Editas Medicine partner on CRISPR genome editing medicines for eye diseases

Wednesday, March 15, 2017

Allergan, a global pharmaceutical company, and Editas Medicine, a genome editing company, have announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently in preclinical development.

[Read More]

Novo Nordisk, Servier, Otsuka, Teva among top sponsors

Wednesday, March 1, 2017

Sponsors have done a good job of maintaining, but not improving, the overall quality of their relationships with investigative sites during the past two years, according to a new CenterWatch survey, but performance gaps have widened across several of the attributes sites identify as the most important for conducting a successful study.

[Read More]

A cautiously optimistic healthcare M&A outlook for 2017

Monday, February 13, 2017

Although 2016 was a lackluster year for megadeals in healthcare, a recent flurry of big deals has Wall Street investors cautiously optimistic that 2017 will bring new mergers and big-ticket acquisitions. An increasingly competitive landscape in healthcare, coupled with signs that the new U.S. presidential administration may usher in more business-friendly policies, could spur major deals in the upcoming year.

[Read More]

Align Biopharma launched as industry standards group

Monday, January 30, 2017

Six of the top 25 largest global pharmaceutical companies announced the formation of Align Biopharma, a new group dedicated to setting technology standards that will make it faster and easier for healthcare professionals (HCPs) to connect with the life sciences industry. Founding members, with input from across the industry, will develop open standards and solutions for companies to streamline how HCPs get the drug and treatment information they need to deliver improved care to patients.

[Read More]

Allergan to acquire Tobira Therapeutics for $1.7B

Wednesday, September 21, 2016

Allergan, a global pharmaceutical company, and Tobira Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, have entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion.

[Read More]